Category: Recent News
Researchers in the Laboratory of Addictive Disorders have discovered that impulsivity is a risk factor for food addiction . Results of the study, published online in Neuropsychopharmacology , suggest that impulsivity promotes pathological overeating.
Dr. Terry Gibbs receives the Excellence in Education and Mentoring Award from the Neurosteroid Congress
Terrell Gibbs, Ph.D., Associate Professor of Pharmacology & Experimental Therapeutics, received the Excellence in Education and Mentoring Award at the Neurosteroid Congress held on April 3, 2014 in Durham, North Carolina.
Terry has served the scientific community with distinction for over 30 years. With undergraduate and doctoral training at MIT and Harvard Medical School, respectively, Terry pursued his interests in neuropharmacology, first at Downstate Medical Center and then at Boston University. His research has involved elucidation of the molecular mechanisms of CNS abnormalities such as autism and of CNS classes of agents such as benzodiazepines and neurosteroids. A long-standing collaboration with David Farb, Ph.D., Chair of Pharmacology at BU, has been an especially productive one in their joint efforts in the pursuit of molecular mechanisms of CNS phenomena. His work as a faculty member has also been characterized by a strong commitment to the education of students in various professional degree programs. Terry has played a key role in the design and implementation of the curriculum for the Biomolecular Pharmacology Predoctoral Training Program at Boston University, supported by NIGMS since 1997. He has guided innumerable PhD candidates through the concepts underlying ligand-receptor interactions, preparation for and successful completion of qualifying examinations, and the rigors of dissertation writing and defense. Medical, dental, and MA students at Boston University have also benefited from his remarkable skill at explaining the principles of pharmacology and the actions of drugs affecting the peripheral and central nervous system. All medical students over the past 23 years have learned the principles of pharmacodynamics under his tutelage and that his dedication to teaching the foundation of pharmacological principles has been a key component of their success on the boards.
Terry’s interest in pharmacologic research in many areas, and the rationale evaluation of evidence of drug efficacy and safety, have been hallmarks of his approach as an educator and served as an outstanding role model for both students and colleagues. His contributions to research have been numerous in the fields of benzodiazepines as modulators of GABAergic function and neuroactive steroids.
At the Student Award Ceremony on Match Day, March 21, 2014, Rebecca Burke was awarded the Joseph Cochin Award in Pharmacology and Medical Ethics. This award honors the memory of Joseph Cochin, MD, PhD, who served as Professor of Pharmacology and Experimental Therapeutics at BUSM for many years. Dr. Cochin was an internationally recognized expert on opioid analgesia, pain control and medical ethics. Becky, a student in the Biomolecular Pharmacology Training Program from 2008-2012, received this award in recognition of her high achievement in pharmacology and accomplishments in research under the mentorship of Jan K. Blusztajn, PhD. Becky will receive her MD and PhD degrees at the BUSM May Graduation Ceremony and will continue her professional training with a residency at the University of Virginia in Neurological Surgery. Congratulations to Becky!
Richard D. Wainford, Ph.D., F.A.H.A., Assistant Professor of Pharmacology and Medicine, Division of Cardiovascular Medicine and member of The Whitaker Cardiovascular Institute at Boston University School of Medicine, has been awarded the 2014 Arthur C. Guyton Award for Excellence in Integrative Physiology and Medicine by The American Physiology Society (APS). This award is given annually to an individual who demonstrates outstanding promise based on his/her research program in feedback controls systems, quantitative modeling, and integrative physiology. The recipient is selected by members of the APS Awards Committee. In addition to the prestige of the award, the recipient is given $15,000 to support their research. Formal presentation of the Arthur C. Guyton Award will take place at the APS Business Meeting at the 2014 Experimental Biology Annual Meeting in San Diego, CA on April 29, 2014.
As Director of the Laboratory of Cardiovascular Renal Research, Dr. Wainford’s research focuses on the central neural control of fluid and electrolyte homeostatis and blood pressure regulation. Please visit Dr. Wainford’s Laboratory website to learn more about his research.
Dr. Camron Bryant’s symposium proposal for the 2014 Annual Genes, Brain and Behavior Meeting of the International Behavioural and Neural Genetics Society Meeting has been accepted as one of six symposia scheduled for this year’s meeting. The 16th annual conference will be held in Chicago, IL from May 10-13.
The title of the symposium that Dr. Bryant will chair is, “Behavioral, neural and genetic studies of compulsive eating in model organisms and humans.” The objective of this symposium is to highlight recent behavioral, neural, and genetic studies of compulsive eating that lie within the framework of addiction and to inform future studies in model organisms and humans.
Congratulations, Dr. Bryant!
Shelley J. Russek, PhD, professor of pharmacology at Boston University School of Medicine (BUSM), and director of the School’s Graduate Program for Neuroscience, was recently honored with an award from the CURE (Citizens United for Research in Epilepsy) Foundation. The prestigious award, given as well to her colleague Amy Brooks-Kayal, MD, from University of Colorado Denver, will fund research studies for new drugs for epilepsy treatment.
Approximately 65 million people worldwide have epilepsy. Although certain brain injuries are known to predispose someone to epilepsy, there are no treatments that reduce this risk. Russek and her colleagues have found that an important cellular signaling pathway, the JAK/STAT pathway, is activated after brain injuries that lead to epilepsy, and that inhibiting this activation reduces subsequent seizure frequency in an experimental model. “We expect to identify lead JAK/STAT inhibitors that can be advanced towards clinical testing to prevent or inhibit development of acquired epilepsy following brain injury,” explained Russek.
CURE was founded by parents of children with epilepsy who were frustrated with their inability to protect their children from the devastation of seizures and the side effects of medications. Unwilling to sit back and accept the debilitating effects of epilepsy, these parents joined forces to spearhead the search for a cure. Each year, grants are funded based on promising trends in the field and the potential for breakthroughs in a specified area. Russek was selected with the assistance of the CURE Scientific Advisory Board, the Lay Review Council, and the scientific peer reviewers who generously volunteer their time to CURE.
CURE has raised more than $26 million to fund research and other initiatives. CURE funds seed grants to young and established investigators to explore new areas and collect the data necessary to apply for further funding by the National Institutes of Health. To date, CURE has awarded 151 cutting-edge projects.
Originally posted on the Boston University Medical Campus website.
The Peter F. McManus Charitable Trust Foundation recently honored Dr. Valentina Sabino for the second time with a grant to research the causes of alcohol addiction. The title of her approved project is “Neurobiological Bases of Alcohol Addiction.”
According to Dr. Sabino, “alcoholism constitutes one of the most serious public health problems worldwide. The World Health Organization estimates that about 2 billion people worldwide consume alcoholic beverages, of which 76.3 million have alcohol use disorders. Alcohol is estimated to cause 20%–30% of esophageal cancer, liver cancer and cirrhosis, homicide, seizures, and motor vehicle accidents, causing 3.2% of the total deaths.
This project will systematically explore the role of an understudied receptor system, the Sigma receptors, in genetic and chronic ethanol-induced animal models of alcoholism. The focus will be the Nucleus Accumbens, an important brain region for alcohol and drug addiction, proposed as being the specific region where Sigma receptors mediated neuroplasticity in addicted brains.
These experiments will provide insights into this novel receptor system as a key mechanism involved in excessive drinking and alcohol-seeking behavior and propose a novel therapeutic target for alcohol addiction.”
Dr. Sabino received her Ph.D. in Pharmacology in 2006. She is an Assistant Professor in the Department of Pharmacology & Experimental Therapeutics and Department of Psychiatry, and Co-Director of the Laboratory of Addictive Disorders at Boston University School of Medicine.
Congratulations, Dr. Sabino!
Dr. Camron Bryant has been selected as the recipient of the 2014 IBANGS Young Scientist Award. The Young Scientist Award honors a scientist who is 7 or fewer years post first faculty or faculty-equivalent appointment, and whose area of research is in behavioural and neural genetics. Key considerations are the scientific importance of research discoveries, record of achievement and future scientific plans and projected impact on the field.
Congratulations, Dr. Bryant!
I am pleased to share that Benjamin Wolozin, MD, PhD, Professor, Pharmacology and Neurology, was awarded the Alzheimer’s Association Zenith Fellows Award. Initiated in 1991, the award provides support for cutting edge basic science or biomedical research that addresses fundamental problems related to early detection, etiology pathogenesis, treatment and/or prevention of Alzheimer’s disease (AD). The award is valued at $450,000, which will be dispersed over three years.
The Wolozin Lab won the award with its proposal “It Takes TIA to Tangle: The Role of RNA Binding Proteins in AD.” The laboratory already has discovered a RNA binding protein that induces tau misfolding, one of the essential steps that leads to cognitive loss in AD. This award will allow the Wolozin Lab to experimentally induce the misfolding, investigate the factors that regulate the misfolding and in the future, potentially design therapeutics to prevent the misfolding.
Please join me in congratulating Dr. Wolozin on this award.Karen Antman, MD Provost, Boston University Medical Campus Dean, School of Medicine Professor of Medicine
Kenneth J. Rhodes, Ph.D., Vice President of Neurology Discovery at Biogen Idec and an alumni of the Boston University Pharmacology Training Program, led the team of researchers that developed Tecfidera, an oral medication that defends against relapsing Multiple Sclerosis (MS).
The Food and Drug Administration recently approved Tecfidera, also known as dimethyl fumarate, for treating relapsing multiple sclerosis. This new drug delays progression of physical disability and slows the development of brain lesions associated with MS. It also reduces the inflammation caused when the immune system attacks myelin, which ultimately results in less damage to myelin in the body. In a Biogen Idec press release, Dr. Kenneth Rhodes stated that, “these exciting results support further research, as the data suggest that neublastin may have the potential to promote sensory neuronal regeneration and functional recovery following injury. The neublastin program is part of Biogen Idec’s commitment to innovative neurological science and discovery.”
According to the Boston Business Journal, Tecfidera “tops the list of the biggest potential revenue-generating drugs launched so far this year in the U.S., with expected sales of $2.9 billion by 2018.”
Dr. Kenneth Rhodes joined Biogen Idec in May 2007 after spending ten years in the Neuroscience Department at Wyeth, where he also led neurodegeneration drug discovery teams researching MS among epilepsy, stroke, Parkinson’s and Alzheimer’s disease. He served as a postdoctoral trainee under the mentorship of Dr. David H. Farb, Professor and Chair of Pharmacology at Boston University School of Medicine, from 1992-1993. Dr. Rhodes has published over 50 research papers in peer-reviewed journals such as Nature, Neuron, and the Journal of Neuroscience and most recently was the Keynote Speaker for the 2013 BU-Pfizer Symposium on “Therapeutic Innovation: Oxidative Stress and the Next Generation of Discovery” held November 5, 2013.